Coherus Biosciences | CHRS - Fremdkapital





Fremdkapital Veränderung Datum
AbbVie USD 64.53B 5.59B 2026-03
Acadia Pharmaceuticals USD 0 0 2025-03
Akebia Therapeutics USD 36.39M 11.85M 2026-03
ALKERMES USD 1.48B 7.23M 2026-06
Alnylam Pharmaceuticals USD 2.47B 6.56M 2026-06
Amgen USD 51.89B 1.88B 2026-03
Baxter International USD 8.62B 6M 2026-06
Biogen USD 7.29B 1B 2026-06
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Coherus Biosciences USD 51.08M 496K 2025-12
Eli Lilly USD 39.37B 1.5B 2026-03
Fujifilm JPY 607.03B 35.21B 2026-03
Gilead Sciences USD 20.86B 1.27B 2026-03
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
Merck USD 46.67B 77M 2026-03
Myriad Genetics USD 120.7M 400K 2026-06
Pacira USD 367.66M 4.53M 2026-03
Perrigo USD 3.62B 17.5M 2026-03
Pfizer USD 60.57B 1.08B 2026-03
PTC Therapeutics USD 535.52M 248.58M 2026-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
Teva Pharmaceutical Industries USD 12.09B 1.92B 2026-06
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12
Xencor USD 82.12M 5.64M 2026-03
Zoetis USD 9.04B 3M 2026-03